Modality
siRNA
MOA
CD47i
Target
USP1
Pathway
PI3K/AKT
MyelofibrosisMS
Development Pipeline
Preclinical
Jan 2020
→ Oct 2031
PreclinicalCurrent
NCT08620858
1,208 pts·MS
2021-08→2030-05·Recruiting
NCT07307307
2,861 pts·Myelofibrosis
2020-01→2031-10·Completed
4,069 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2030-05-064.1y awayInterim· MS
2031-10-025.5y awayInterim· Myelofibrosis
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Preclinical
Complet…
Preclinical
Recruit…
Catalysts
Interim
2030-05-06 · 4.1y away
MS
Interim
2031-10-02 · 5.5y away
Myelofibrosis
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08620858 | Preclinical | MS | Recruiting | 1208 | FEV1 |
| NCT07307307 | Preclinical | Myelofibrosis | Completed | 2861 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| BGN-3859 | BeiGene | Approved | PSMA | |
| Zanurapivir | Neurocrine | NDA/BLA | EGFR |